Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 Am 1

Total Page:16

File Type:pdf, Size:1020Kb

Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 Am 1 Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 am HEMOSTASIS Primary vs. Secondary vs. Tertiary • Primary Hemostasis – Platelet Plug Formation Hemostasis/Thrombosis I – Dependent on normal platelet number & function – Initial Manifestation of Clot Formation •Secondary Hemostasis Normal Hemostasis/Thrombosis; – Activation of Clotting Cascade Î Deposition & Stabilization of Assessment of Clotting System Fibrin • Tertiary Hemostasis – Dissolution of Fibrin Clot – Dependent on Plasminogen Activation HEMOSTATIC DISORDERS HEMOSTASIS & THROMBOSIS Suspicions • Spontaneous bleeding •Platel ets •Prolonged or excessive bleeding after • Coagulation Cascade procedures or trauma • Regulation of Coagulation • Simultaneous bleeding from multiple sites HEMOSTATIC DEFECTS CIRCULATORY SYSTEM Bleeding Platelet Coagulation Problem Disorder Abnormality • Low volume, high pressure system Petechiae + - • Efficient for nutrient delivery to tissues • Prone to leakage 2º to endothelial surface Bleeding M ucous Deep Tissue damage Sites MbM em b rane • Small volume loss large decrease in Î Time of Immediate Delayed nutrient delivery onset of • Minimal extravasation in critical areas bleeding Î irreparable damage/death of organism Ecchym oses ++ /Hem atom as 1 Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 am HEMOSTATIC ABNORMALITIES "Screening Tests" (History) • Dental Extractions • Prior Surgery/Biopsy • EbiiEasy bruising • Heavy menses • Deliveries • Blood transfusion PLATELET ACTIVATION PLATELETS • Anucleate cellular fragments; multiple granules, multiple organelles • Synthesis controlled by IL-6, IL-3, IL-11, & thrombopoietin • Circulate as inactive, non-binding concave discs • On stimulation, undergo major shape change • Develop receptors for clotting factors • Develop ability to bind to each other & subendothelium Resting vWF Platelets Platelet Adhesion Initial Thrombin Formation IIa TR II IIa X Xa VIIa -TF 2 Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 am PLATELET ACTIVATION II IIa X Xa VIIa Platelet -TF Activation Platelet Release TxA2, ADP, Serotonin, Fibrinogen, Thrombospondin II IIa X Xa VIIa -TF PLATELET PLUG FORMATION COAGULATION CASCADE General Features • Zymogens converted to enzymes by limited proteolysis • Complex formation requiring calcium, phospholipid surface , cofactors • Thrombin converts fibrinogen to fibrin monomer • Fibrin monomer crosslinked to fibrin • Forms "glue" for platelet plug 3 Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 am COAGULATION CASCADE Platelet Release TxA2, ADP, Serotonin, Fibrinogen, Thrombospondin VIII VIIIa V Va II IIa IX IXa X Xa VIIa VIIa -TF -TF THROMBIN Tenase/Prothrombinase complex assembly • Serine protease X Xa • Cleaves fibrinogen to fibrin II IIa VIIIa/IXa • Activates V to Va, VIII to VIIIa Va/Xa VIIIa R • Activates platelets-cleaves thrombin receptor Va R • Activates XIII to XIIIa • In presence of thrombomodulin activates Protein C to APC FIBRIN FORMATION A A COAGULATION CASCADE B B T F XIIIa 4 Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 am VITAMIN K DEPENDENT CARBOXYLASE BLEEDING TIME vs. PLATELET COUNT • Post-translational modification 400 • Factors II, VII, IX, X; proteins C & S 350 • Converts 1st 7-12 glutamic acids to 300 250 γ-carboxyglutamic acid nt (x 1000) u 200 • Confers calcium binding and lipid binding on these 150 proteins 100 50 Platelet co • Without vitamin K, secrete des- 0 γ-carboxyglutamic acid containing proteins 3.5 4 4.5 5 5.5 7 9 12 15 25 30 (inactive in coagulation) Minutes γ -CARBOXYGLUTAMIC ACID COAGULATION CASCADE COO- COO- COO- CH2 CH O2,CO2 CH2 CH2 NH + CH NH + CH 3 Vit K 3 Carboxylase COO- COO- Glu γ-carboxy Glu PLATELET FUNCTION STUDIES Clotting Tests • Recalcification times • Blood collected in sodium citrate, a weak • Bleeding Time calcium chelator • Plate let C ount • AtdidtdliAmount designed to drop calcium • Platelet Aggregation Studies concentration to < 1 mM • At that level, blood won’t clot spontaneously • RBC’s & platelets centrifuged off, leaving plasma (unclotted liquid portion of blood) 5 Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 am COAGULATION CASCADE INTRINSIC PATHWAY Prothrombin Time FXII FXIIa Surface Active aPTT Components •Mixture of: FXI HMWK – 50% patient’s platelet poor plasma FXIa FIX Ca+2 FIXa +2 – 25% Mixture of Tissue Factor & phospholipid T Ca species VIII VIIIa VIIIa/IXa/PL Middle Components FX +2 – 25% Calcium chloride (to bring final calcium Ca FXa Ca+2 concentration to c. 3-5 mM) T – Time to clot formation measured V Va Va/Xa/PL PT Ca+2 Common Pathway T FG F COAGULATION CASCADE COAGULATION CASCADE EXTRINSIC PATHWAY Contact Phase Prothrombin Time (PT) TF FVII Prekallikrein FVIIa Ca+2 Kallikrein VIIa/TF F XII Middle Components FX Ca+2 HMWK FXa Ca+2 T F XIIa V Va Va/Xa/PL PT Ca+2 Common Pathway T FG F XI F F XIa COAGULATION CASCADE Intermediate Phase aPTT (activated partial thromboplastin time) F VII/TF Ca+2 • 50% patient’s platelet-poor plasma F VIIa/TF • 25% mixture of phospholipid & surface active agent (Celite, Kaolin) XIa VIIa/TF/PL • 25% Calcium Chloride to bring calcium F IX Ca+2 Ca+2 concentration to 3-5 mM T • Time to clot formation measured VIII VIIIa + F IXa IXa/VIIIa/PL Tenase Complex +2 F X Ca F Xa 6 Platelets/Introduction to Hemostasis Monday, April 21 – 10:00 am COAGULATION CASCADE Common Pathway IXa/VIIIa/PL VIIa/TF/PL F X +2 F X Ca+2 Ca V Va+ FXF Xa X/V/PLXa/Va/PL PT Ca+2 Prothrombinase Complex T Fibrinogen Fibrin monomer CLOTTING ASSAYS Specific factors/Inhibitors • Deficiency states of every clotting protein described • 50% of any clotting factor will yield normal PT and/or aPTT • Mix 1/2 patient plasma with 1/2 factor deficient plasma; then perform PT and/or aPTT • Factor deficient plasma with missing factor will Î prolonged clotting time; all others WNL • If more than one clotting assay prolonged, implies inhibitor to clotting protein 7.
Recommended publications
  • Recombinant Factors for Hemostasis
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Chemical & Biomolecular Engineering Theses, Chemical and Biomolecular Engineering, Dissertations, & Student Research Department of Summer 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra University of Nebraska at Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/chemengtheses Part of the Biochemical and Biomolecular Engineering Commons Calcaterra, Jennifer, "Recombinant Factors for Hemostasis" (2010). Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research. 5. https://digitalcommons.unl.edu/chemengtheses/5 This Article is brought to you for free and open access by the Chemical and Biomolecular Engineering, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Recombinant Factors for Hemostasis by Jennifer Calcaterra A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Interdepartmental Area of Engineering (Chemical & Biomolecular Engineering) Under the Supervision of Professor William H. Velander Lincoln, Nebraska August, 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra, Ph.D. University of Nebraska, 2010 Adviser: William H. Velander Trauma deaths are a result of hemorrhage in 37% of civilians and 47% military personnel and are the primary cause of death for individuals under 44 years of age. Current techniques used to treat hemorrhage are inadequate for severe bleeding. Preliminary research indicates that fibrin sealants (FS) alone or in combination with a dressing may be more effective; however, it has not been economically feasible for widespread use because of prohibitive costs related to procuring the proteins.
    [Show full text]
  • Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: a Single-Centre, Observer-Blinded, Randomized Controlled Trial (Trace)
    TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) by Adriana Micheline Workewych A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Adriana Micheline Workewych 2018 TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) Adriana Micheline Workewych Master of Science Institute of Medical Science University of Toronto 2018 ABSTRACT Chronic subdural hematoma (CSDH) is a frequent consequence of head trauma, particularly in older individuals. Given the aging of populations globally, its incidence is projected to increase substantially. Hyperfibrinolysis may be central to CSDH enlargement by causing excessive clot degradation and liquefaction, impeding resorption. The only current standard treatment for CSDH is surgery, however, up to 31% of residual hematomas enlarge, requiring reoperation. Tranexamic acid (TXA), an antifibrinolytic medication that prevents excessively rapid clot breakdown, may help prevent CSDH enlargement, potentially eliminating the need for repeat surgery. To evaluate the feasibility of conducting a trial investigating TXA efficacy in residual CSDH, we conducted an observer-blinded, pilot randomized controlled trial (RCT). We showed this trial was feasible and safe, reporting only minor to moderate AEs, and an attrition rate of 4%. The results from this study will inform the conduct of a double-blinded RCT investigating TXA efficacy in post-operative CSDH management. ii ACKNOWLEDGEMENTS First, I would like to thank my supervisor Dr. Michael Cusimano, my mentor for nearly six years. You have always given me more opportunity than I could have ever hoped for – I could not ask for a more dedicated teacher.
    [Show full text]
  • Path Ggf 5 2020.Pdf
    Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic clot at the site of a vascular injury. Thrombosis involves blood clot formation within intact vessels. Both hemostasis and thrombosis involve three components: the vascular wall, platelets and the coagulation cascade. Elements of the Hemostatic process • Endothelium • Anti-thrombosis • Pro-thrombosis • Platelets • Platelet-endothelial cell interaction • Coagulation cascade http://www.as.miami.edu/chemistry/2086/chapter_21/NEW-Chap21_class_part1_files/image002.jpg After initial injury there is a brief period of arteriolar vasoconstriction mediated by reflex neurogenic mechanisms and augmented by the local secretion of factors such as endothelin (a potent endothelium-derived vasoconstrictor) The effect is transient, however, and bleeding would resume if not for activation of the platelet and coagulation systems. Endothelial injury exposes highly thrombogenic subendothelial extracellular matrix (ECM), facilitating platelet adherence and activation. Activation of platelets results in a dramatic shape change (from small rounded discs to flat plates with markedly increased surface area), as well as the release of secretory granules. Within minutes the secreted products recruit additional platelets (aggregation) to form a hemostatic plug; this process is referred to as primary hemostasis. http://www.ouhsc.edu/platelets/Platelet%20Pic s/Platelets3.jpg http://medcell.med.yale.edu/histology/blood_bone_marr ow_lab/images/platelets_em.jpg Tissue factor is also exposed at the site of injury. Also known as factor III and thromboplastin, tissue factor is a membrane-bound procoagulant glycoprotein synthesized by endothelial cells. It acts in conjunction with factor VII (see below) as the major in vivo initiator of the coagulation cascade, eventually culminating in thrombin generation.
    [Show full text]
  • The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation Using ADP
    RESEARCH ○○○○○○○○ The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation using ADP ROBERT F CORNELL, TIM R RANDOLPH ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ OBJECTIVE: Determine the minimum concentration of plasma INDEX TERMS: ADP; aggregation; fibrinogen; platelets. fibrinogen needed to stimulate the aggregation of platelets, col- lected from normal subjects, using ADP. Clin Lab Sci 2001;15(1):30 DESIGN: Platelet rich plasmas (300 x 109 platelets/L) were made Robert F Cornell II was a student in the Department of Clinical and adjusted to final fibrinogen concentrations of 75, 19, 5, and 0 Laboratory Science, Saint Louis University Health Sciences Center, St mg/dL using fibrinogen free serum. Each fibrinogen concentra- Louis MO when this research was done. Downloaded from tion in all twelve subjects was aggregated with ADP. Tim R Randolph MS is an Assistant Professor in the Department of SETTING: Research laboratory in the Department of Clinical Clinical Laboratory Science, School of Allied Health Professions, Saint Laboratory Science at Saint Louis University. Louis University Health Sciences Center, St Louis MO. PARTICIPANTS: Twelve healthy volunteers of both genders, be- Address for correspondence: Tim R Randolph MS, Saint Louis Uni- http://hwmaint.clsjournal.ascls.org/ tween the ages of 18 and 60 years who were not pregnant and versity School of Allied Health Professions, Department of Clinical Labo- weighed at least 110 pounds were included in the study. Subjects ratory Science, Room 3096, 3437 Caroline St, St Louis MO 63104. were excluded from the study if they had ingested aspirin within (314) 577-8518, (314) 577-8503 (fax). [email protected] one week prior to blood collection.
    [Show full text]
  • Biomechanical Thrombosis: the Dark Side of Force and Dawn of Mechano-­ Medicine
    Open access Review Stroke Vasc Neurol: first published as 10.1136/svn-2019-000302 on 15 December 2019. Downloaded from Biomechanical thrombosis: the dark side of force and dawn of mechano- medicine Yunfeng Chen ,1 Lining Arnold Ju 2 To cite: Chen Y, Ju LA. ABSTRACT P2Y12 receptor antagonists (clopidogrel, pras- Biomechanical thrombosis: the Arterial thrombosis is in part contributed by excessive ugrel, ticagrelor), inhibitors of thromboxane dark side of force and dawn platelet aggregation, which can lead to blood clotting and A2 (TxA2) generation (aspirin, triflusal) or of mechano- medicine. Stroke subsequent heart attack and stroke. Platelets are sensitive & Vascular Neurology 2019;0. protease- activated receptor 1 (PAR1) antag- to the haemodynamic environment. Rapid haemodynamcis 1 doi:10.1136/svn-2019-000302 onists (vorapaxar). Increasing the dose of and disturbed blood flow, which occur in vessels with these agents, especially aspirin and clopi- growing thrombi and atherosclerotic plaques or is caused YC and LAJ contributed equally. dogrel, has been employed to dampen the by medical device implantation and intervention, promotes Received 12 November 2019 platelet thrombotic functions. However, this platelet aggregation and thrombus formation. In such 4 Accepted 14 November 2019 situations, conventional antiplatelet drugs often have also increases the risk of excessive bleeding. suboptimal efficacy and a serious side effect of excessive It has long been recognized that arterial bleeding. Investigating the mechanisms of platelet thrombosis
    [Show full text]
  • BLOOD COAGULATION TESTS 17 Lea E
    HEMATOLOGY: BLOOD COAGULATION TESTS 17 Lea E. Dela Peña Normal hemostasis involves a complex interaction among the vascular subendothe- OBJECTIVES lium, platelets, coagulation factors, and proteins that promote clot formation, clot degradation and inhibitors of these substances. Disruption in normal hemostasis can After completing this chapter, the result in bleeding or excessive clotting. Bleeding can be caused by trauma or damage reader should be able to to vessels, acquired or inherited deficiencies of coagulation factors, or physiological • Describe the role of platelets, disorders of platelets, whereas excessive clotting can result from abnormalities of the the coagulation cascade, and vascular endothelium, alterations in blood flow, or deficiencies in clotting inhibitors. fibrinolytic system in normal Clinicians must monitor the hemostasis process in individual patients to ensure hemostasis their safety from an imbalance in this complex system. For example, practitioners routinely order platelet tests in patients on certain antineoplastic medications to • List the laboratory tests used assess for thrombocytopenia. Likewise, clinicians closely monitor coagulation tests to assess platelets and discuss for patients receiving anticoagulants to prevent thromboembolic or hemorrhagic factors that may influence their complications. Overall, the hemostatic process is intricate and requires a clinician results knowledgeable in its dynamics for quality assessment. • List the laboratory tests used This chapter reviews normal coagulation physiology,
    [Show full text]
  • Hematopoiesis and Hemostasis
    Hematopoiesis and Hemostasis HAP Susan Chabot Hematopoiesis • Blood Cell Formation • Occurs in red bone marrow – Red marrow - found in flat bones and proximal epiphyses of long bones. • Each type of blood cell is produced in response to changing needs of the body. • On average, an ounce of new blood is produced each day with about 100 billion new blood cells/formed elements. Hemocytoblast • Hemo- means blood • Cyto- means cell • -blast means builder • Blood stem cell found in red bone marrow. • Once the precursor cell has committed to become a specific blood type, it cannot be changed. Hemocytoblast Erythropoiesis • Erythrocyte Formation • Because they are anucleated, RBC’s must be regularly replaced. – No info to synthesize proteins, grow or divide. • They begin to fall apart in 100 - 120 days. • Remains of fragmented RBC’s are removed by the spleen and liver. • Entire development , release, and ejection of leftover organelles takes 3-5 days. Normal RBC’s Reticulocytes • The stimulus for RBC production is the amount of OXYGEN in the blood not the NUMBER of RBC’s. • The rate of RBC production is controlled by the hormone ERYTHROPOIETIN. Leuko- and Thrombopoiesis • Leukopoesis = WBC production • Thrombopoesis = platelet production • Controlled by hormones Leukopoesis Thrombopoesis • (CSF) Colony • Thrombopoetin stimulating factor • Little is known • Interleukins about this – Prompts WBC process. production – Boosts other immune processes including inflammation. HEMOSTASIS Hemostasis • Hemo- means blood • -stasis means standing still – Stoppage of bleeding • Fast and localized reaction when a blood vessel breaks. • Involves a series of reactions. • Involves substances normally found in plasma but not activated. • Occurs in 3 main phases Phases of Hemostasis • Step 1: Vascular Spasm – Vasoconstriction, narrowing of blood vessels.
    [Show full text]
  • Notch and TLR Signaling Coordinate Monocyte Cell Fate and Inflammation
    RESEARCH ARTICLE Notch and TLR signaling coordinate monocyte cell fate and inflammation Jaba Gamrekelashvili1,2*, Tamar Kapanadze1,2, Stefan Sablotny1,2, Corina Ratiu3, Khaled Dastagir1,4, Matthias Lochner5,6, Susanne Karbach7,8,9, Philip Wenzel7,8,9, Andre Sitnow1,2, Susanne Fleig1,2, Tim Sparwasser10, Ulrich Kalinke11,12, Bernhard Holzmann13, Hermann Haller1, Florian P Limbourg1,2* 1Vascular Medicine Research, Hannover Medical School, Hannover, Germany; 2Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; 3Institut fu¨ r Kardiovaskula¨ re Physiologie, Fachbereich Medizin der Goethe-Universita¨ t Frankfurt am Main, Frankfurt am Main, Germany; 4Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany; 5Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany; 6Mucosal Infection Immunology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany; 7Center for Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; 8Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; 9German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Mainz, Germany; 10Department of Medical Microbiology and Hygiene, Medical Center of the Johannes Gutenberg- University of Mainz, Mainz, Germany; 11Institute for Experimental Infection Research, TWINCORE, Centre for
    [Show full text]
  • Human Alveolar Macrophages Synthesize Factor VII in Vitro
    Human alveolar macrophages synthesize factor VII in vitro. Possible role in interstitial lung disease. H A Chapman Jr, … , O L Stone, D S Fair J Clin Invest. 1985;75(6):2030-2037. https://doi.org/10.1172/JCI111922. Research Article Both fibrin and tissue macrophages are prominent in the histopathology of chronic inflammatory pulmonary disease. We therefore examined the procoagulant activity of freshly lavaged human alveolar macrophages in vitro. Intact macrophages (5 X 10(5) cells) from 13 healthy volunteers promoted clotting of whole plasma in a mean of 65 s. Macrophage procoagulant activity was at least partially independent of exogenous Factor VII as judged by a mean clotting time of 99 s in Factor VII-deficient plasma and by neutralization of procoagulant activity by an antibody to Factor VII. Immunoprecipitation of extracts of macrophages metabolically labeled with [35S]methionine by Factor VII antibody and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a labeled protein consistent in size with the known molecular weight of blood Factor VII, 48,000. The addition of 50 micrograms of unlabeled, purified Factor VII blocked recovery of the 48,000-mol wt protein. In addition, supernatants of cultured macrophages from six normal volunteers had Factor X-activating activity that was suppressed an average of 71% after culture in the presence of 50 microM coumadin or entirely by the Factor VII antibody indicating that Factor VII synthesized by the cell was biologically active. Endotoxin in vitro induced increases in cellular tissue factor but had no consistent effect on macrophage Factor VII activity. We also examined the tissue factor and Factor VII activities […] Find the latest version: https://jci.me/111922/pdf Human Alveolar Macrophages Synthesize Factor VII In Vitro Possible Role in Interstitial Lung Disease Harold A.
    [Show full text]
  • Ferric Sulfate Hemostasis: Effect on Osseous Wound Healing, II, with Curettage and Irrigation
    0099-2399/93/1904-0174/$03.00/0 JOURNAL OF ENDODONTICS Printed in U.S.A. Copyright © 1993 by The American Association of Endodontists VOL. 19, No. 4, APRIL 1993 Ferric Sulfate Hemostasis: Effect on Osseous Wound Healing, II, With Curettage and Irrigation Billie G. Jeansonne, DDS, PhD, William S. Boggs, DDS, MS, and Ronald R. Lemon, DMD Hemorrhage control is often a problem for the clini- MATERIALS AND METHODS cian during osseous surgery. Ferric sulfate is an effective hemostatic agent, but with prolonged ap- The experiments were performed in 12 New Zealand White plication to an osseous defect can cause persistent rabbits (2.3 to 3.7 kg). Anesthesia was obtained by the intra- inflammation and delayed healing. The purpose of muscular injection of a combination of xylazine (7 mg/kg), ketamine (30 mg/kg), and atropine (0.3 mg/kg). On both this investigation was to evaluate the effectiveness sides of the mandible, an incision was made along the alveolar of ferric sulfate as a hemostatic agent and to deter- crest in the naturally edentulous space between the incisor mine its effect on healing after thorough curettage and premolar teeth. An envelope flap was reflected to expose and irrigation from osseous surgical wounds. Stand- the alveolar cortical bone. An osseous defect (3 mm in di- ard size osseous defects were created bilaterally in ameter, 2 mm into cancellous bone) was created on each side the mandibles of rabbits. Ferric sulfate was placed with a #8 round bur. All defects were curetted and irrigated in one defect until hemostasis was obtained; the with saline.
    [Show full text]
  • Pulmonary Megakaryocytes in Coronavirus Disease 2019 (COVID-19): Roles in Thrombi and Fibrosis
    Published online: 2020-09-03 Commentary 831 Pulmonary Megakaryocytes in Coronavirus Disease 2019 (COVID-19): Roles in Thrombi and Fibrosis Jecko Thachil, MD, FRCP1 Ton Lisman, PhD2 1 Department of Haematology, Manchester Royal Infirmary, Address for correspondence Jecko Thachil, MD, FRCP, Department of Manchester, United Kingdom Haematology, Manchester Royal Infirmary, Oxford Road, Manchester 2 Surgical Research Laboratory and Section of Hepatobiliary Surgery M13 9WL, United Kingdom (e-mail: [email protected]). and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Semin Thromb Hemost 2020;46:831–834. Coronavirus disease 2019 (COVID-19) has already claimed karyocyte presence in the lungs assert that lung megakaryo- many lives and continues to do so in different parts of the cytes just represent a gravity phenomenon noted at autopsy. world. Autopsy reports of patients who succumbed to this viral The mostelegant (and latest)study for validating thelungorigin infection have been published despite concerns about health of platelets comes from Lefrançais et al who directly imaged the care professional safety. One of the unusual findings in COVID- lung microcirculation in mice to provide definite proof for the 19 lung autopsy reports is the increase in pulmonary mega- existence of lung megakaryocytes.8 They also proved that karyocytes.1,2 Although the presence of megakaryocytes in the approximately halfof the total number of platelets or 10 million lungs is a well-established concept in the medical literature, it platelets per hour would be produced by these cells.8 is still not widely accepted in the clinical fraternity.
    [Show full text]
  • The Molecular Basis of Blood Coagulation Review
    Cell, Vol. 53, 505-518, May 20, 1988, Copyright 0 1988 by Cell Press The Molecular Basis Review of Blood Coagulation Bruce Furie and Barbara C. Furie into the fibrin polymer. The clot, formed after tissue injury, Center for Hemostasis and Thrombosis Research is composed of activated platelets and fibrin. The clot Division of Hematology/Oncology mechanically impedes the flow of blood from the injured Departments of Medicine and Biochemistry vessel and minimizes blood loss from the wound. Once a New England Medical Center stable clot has formed, wound healing ensues. The clot is and Tufts University School of Medicine gradually dissolved by enzymes of the fibrinolytic system. Boston, Massachusetts 02111 Blood coagulation may be initiated through either the in- trinsic pathway, where all of the protein components are present in blood, or the extrinsic pathway, where the cell- Overview membrane protein tissue factor plays a critical role. Initia- tion of the intrinsic pathway of blood coagulation involves Blood coagulation is a host defense system that assists in the activation of factor XII to factor Xlla (see Figure lA), maintaining the integrity of the closed, high-pressure a reaction that is promoted by certain surfaces such as mammalian circulatory system after blood vessel injury. glass or collagen. Although kallikrein is capable of factor After initiation of clotting, the sequential activation of cer- XII activation, the particular protease involved in factor XII tain plasma proenzymes to their enzyme forms proceeds activation physiologically is unknown. The collagen that through either the intrinsic or extrinsic pathway of blood becomes exposed in the subendothelium after vessel coagulation (Figure 1A) (Davie and Fiatnoff, 1964; Mac- damage may provide the negatively charged surface re- Farlane, 1964).
    [Show full text]